• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Protodioscin

CAS No. 55056-80-9

Protodioscin ( —— )

产品货号. M18789 CAS No. 55056-80-9

Protodioscin is a major steroidal saponin in dioscoreae rhizome, with anti-hyperlipidemia, anti-cancer properties.

纯度: 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥512 有现货
10MG ¥864 有现货
25MG ¥1746 有现货
100MG 获取报价 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Protodioscin
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Protodioscin is a major steroidal saponin in dioscoreae rhizome, with anti-hyperlipidemia, anti-cancer properties.
  • 产品描述
    Protodioscin is a major steroidal saponin in dioscoreae rhizome, with anti-hyperlipidemia, anti-cancer properties.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    Others
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    55056-80-9
  • 分子量
    1049.21
  • 分子式
    C51H84O22
  • 纯度
    98%
  • 溶解度
    ——
  • SMILES
    C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]2[C@H]3CC=C3[C@@]2(CC[C@@H](C3)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)O)O)O[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)O)C)C)O[C@@]1(CC[C@@H](C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Wang T1, Choi RC, Li J, Li J,et al.Antihyperlipidemic effect of protodioscin, an active ingredient isolated from the rhizomes of Dioscorea nipponica.Planta Med. 2010 Oct;76(15):1642-6.
产品手册
关联产品
  • Ethacridine lactate ...

    Ethacridine lactate monohydrate is an aromatic organic compound based on acridine used as an antiseptic agent.

  • TDCPP

    TDCPP is classified under the chlorinated trialkyl organophosphate flame retardant (OPFR) group of compounds primarily utilized as additives in commercial products.

  • TIC10

    TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.